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Abstract
Background: Nuclear factor-kappa B (NF-B) signaling constitutes a key event in the multistep process of
carcinogenesis, progression and treatment in many cancer types. However, the significance of NF-B pathway for
complex and tissue-specific aspects of head and neck cancer progression, such as invasion and metastasis, is less
understood.
Methods: The expression of NF-B p65 in squamous cell carcinoma of the head and neck (SCCHN) clinical
specimens by immunohistochemistry. The role of NF-B activity in head and neck squamous cell carcinoma was
determined by western blot, reporter assay and EMSA analysis in vitro and metastasis assays in vivo in different
metastatic potential tumor cells. Furthermore, the apoptosis rate and expression of metastasis-related protein such
as MMP9 and VEGF were examined by Annexin V/PI staining and Western blot, respectively.
Results: A higher level of active nuclear-localized NF-B was observed in the metastatic SCCHN specimens group
(p < 0.01). The NF-B activities of SCCHN cell lines with different metastatic potentials were then determined and
in excellent agreement with results found in SCCHN specimens, highly metastatic SCCHN cell lines expressed high
level of NF-B activity. The treatment of highly metastatic SCCHN cells with NF-B inhibitors reduced the in vitro
cell invasion capacity of the cells without affecting the apoptotic rate. Additionally, the NF-B inhibitors
significantly inhibited the experimental lung metastasis of Tb cells and lymph node metastasis of TL cells in nude
mice. Furthermore, the expression of metastasis-related proteins, such as matrix metalloproteinase 9 and vascular
endothelial growth factor, was inhibited by pyrrolidine dithiocarbonate.
Conclusions: This study suggests that NF-B activity significantly contributes to tumor hematologic and lymphatic
metastases and may aid in the development of early detection methods or therapies targeting non-conventional
molecular targets.
Background
Head and neck cancer (HNC) consistently ranks as one
of the most prevalent cancers worldwide. Over 90% of
all HNC are squamous cell carcinomas [1]. Worldwide,
more than 650,000 new cases with HNC are diagnosed
every year [2], and two-thirds of patients with HNC pre-
sent with locally advanced lesions and/or regional lymph
node involvement. In the United States, 35,720 new
cases of oral cavity & pharynx cancer were diagnosed
in 2009[3]. Curative surgery, radiotherapy and
chemotherapy have failed to reduce the overall mortality
rate of head and neck cancers over the past several dec-
ades. Therefore, it is absolutely necessary to determine
the mechanisms contributing to invasion and metastasis
of squamous cell carcinoma of the head and neck
(SCCHN).
Recently, accumulating evidence has suggested that
the nuclear factor-B (NF-B) signaling pathway plays a
critical role in carcinogenesis, protection from apoptosis
and chemoresistance in a number of cancer types,
including head and neck cancer, breast cancer, hepato-
cellular carcinoma and gastric cancer [3-7]. NF-Bi sa
transcription factor that is retained in the cytoplasm by
t h ei n h i b i t o r yp r o t e i nI B. Phosphorylated IBa is
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proteasome, resulting in the liberation of NF-B. NF-B
can then enter the nucleus to regulate the expression of
genes involved in cell proliferation, cell survival and
apoptosis [8,9]. Several studies have suggested that NF-
B is also associated with cancer cell invasion and
metastasis [5,10-13]. However, the presence and role of
NF-B in the invasion and metastasis of cancer is not
clear.
The present study provides evidence that NF-B activ-
ity significantly contributes to tumor invasion and
metastasis. The data presented here demonstrates that
inhibition of the NF-B signaling pathway could reduce
tumor invasion and metastasis in vitro and in vivo.
Therefore, NF-B, as well as its downstream or
upstream signaling effectors, may be effective molecular
targets for the detection or inhibition of SCCHN hema-
tologic and lymphatic metastasis.
Methods
Immunohistochemistry
This study was approved by the Institutional Review
Board of the Ninth People’s Hospital, Shanghai Jiao
Tong University School of Medicine. All specimens for
this study were obtained from surgical samples with
pathological diagnosis and informed consent. The par-
affin-embedded tissue blocks were selected based on
patient diagnosis: primary tumors without lymph node
involvement (Tn), primary tumors with lymph node
involvement (Tm) and the tissues of their paired meta-
static lymph node (Lm). There were a total of 30 spe-
cimens in each group (Table 1). Patients who were
previously treated (radiotherapy or chemotherapy) for
the index tumor or another head and neck primary
tumor within the past five years were excluded. The
tumor size, nodal metastases and distant metastases
(TNM) classification of all tumors was according to
the International Union Against Cancer. The clinical
information was obtained from the surgical pathology
files in the hospital. The relevant clinical parameters,
including age, gender, alcohol use, smoking habits, ori-
ginal primary tumor site and pathology stage, are listed
in Table 2.
NF-B p65 expression in the tissue specimens was
determined using a mouse monoclonal anti-human NF-
B p65 antibody (Sigma-Aldrich). Mouse IgG at a 1:100
dilution was used as a negative control. Immunohisto-
chemical analysis of formalin-fixed, paraffin-embedded
human specimens was performed according to a modi-
fied procedure. Briefly, after deparaffinization with
xylene and rehydration with ethanol, endogenous perox-
idase activity was blocked by incubating the slides in 3%
hydrogen peroxide in methanol for 15 minutes. To
retrieve the antigens, the tissue slides were heated in a
microwave oven in 100 mM sodium citrate buffer (pH
6.0) for 10 minutes and then cooled to room tempera-
ture for 20 minutes. Cover tissue sections with
3-4 drops of protein block buffer (DAKO) and incubate
slides for 15 minutes in humid chamber at room tem-
perature. After being washed in phosphate-buffered sal-
ine (PBS), the slides were incubated with a 1:50 dilution
of the anti-NF-B p65 antibody overnight at 4°C. The
next day, the slides were washed with PBS and incu-
bated with a horseradish peroxidase (HRP)-conjugated
affinity purified goat anti-mouse IgG (H+L) secondary
antibody for one hour at room temperature and with a
biotin-avidin peroxidase conjugate (ABC kit, Vector
Laboratories) for 15 minutes at room temperature. The
substrate (0.1% 3,3 - diaminobenzidine solution; Sigma,
St. Louis, MO) was then added in PBS with 0.01%
hydrogen peroxide. Finally, the slides were counter-
stained with hematoxylin (Vector Laboratories) for
50 seconds and then observed using light microscopy.
The immunoreactivity of the tissue was estimated by
counting the number of nuclear staining-positive cells
per 1 000 tumor cells. Independent counts were made
by three pathologists with no prior knowledge of the
clinical information. The specimens were divided into
five groups: > 80% nuclear staining-positive cells, 50%-
80% nuclear staining-positive cells, 30%-49% nuclear
staining-positive cells, 10%-29% nuclear staining-positive
cells and < 10% nuclear staining-positive cells.
Cell culture
Tca8113, a human SCCHN cell line, was derived from a
patient with a tongue squamous cell carcinoma. The Tb
cell line was selected from the Tca8113 cell line using a
combination of selection in vivo and clone selection
in vitro. Compared to non-metastatic Tca8113, the Tb
cell line demonstrated an increased (up to 100%) metas-
tasis rate in an experimental lung metastasis model
using nude mice. In contrast, TL cells, another deriva-
tive of the Tca8113 cell line, possess high metastatic
potential to regional lymph nodes. The TSCC cell line is
a non-metastatic cell line established at Wuhan Univer-
sity. The OSC-4 cell line has a strong invasion tendency
and was developed at Kochi University, Japan. All five of
these cell lines were maintained in RPMI 1640 with 10%
fetal bovine serum (FBS) supplemented with 1 mM
L-glutamine, 100 U/ml penicillin and 100 U/ml strepto-
mycin and were kept at 37°C and 5% CO2.
Western blot
Cells were treated with 50 ng/mL tumor necrosis factor-
a (TNFa; Cytolab, Peprotech ASIA) for the indicated
time. The cells were then harvested and washed twice
with PBS. The cells were pelleted and lysed with lysis
buffer containing 1% Nonidet P-40, 5% sodium
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date and 1% protease inhibitor cocktail (Sigma-Aldrich,
USA). The protein concentration was determined using
the bicinchoninic acid (BCA) Protein Assay Kit accord-
ing to the manufacturer’s protocol (Pierce), and the cell
extracts were stored at -80°C until use. Before loading,
the protein samples were boiled in sample buffer [62.5
mM Tris-HCl (pH 6.8), 10% (w/v) glycerol, 100 mM
DTT, 2.3% SDS, 0.002% bromophenol blue] for 10 min-
utes. The samples were separated in a 10% SDS-PAGE
gel and transferred to a polyvinylidene difluoride mem-
brane (Amersham Pharmacia Biotech, Arlington
Heights, IL). The membranes were blotted with 5% fat-
free milk overnight at 4°C and probed with the primary
antibodies. The immunocomplexes were visualized using
an HRP-conjugated goat anti-rabbit or anti-mouse
antibody (Promega) and ECL plus reagents (Amersham
Pharmacia Biotech, Arlington Heights, IL). The anti-
IBa, anti-phospho-IBa (serine 32) and anti-phospho-
NF-B p65 (serine 536) polyclonal antibodies were from
Cell Signaling Technology, while the anti-MMP9 and
anti-VEGF antibodies were from Santa Cruz Biotech
(CA, USA).
NF-B luciferase reporter assay
The SCCHN cells (2×10
5)w e r ep l a t e di na6 - w e l ld i s h
and transfected with the 2× NF-B-luciferase plasmid
using Lipofectamine 2 000 according to the manufac-
turer’s instructions (Invitrogen Life Technologies). The
cells were co-transfected with the pPenilla Renilla luci-
ferase reporter to normalize for transfection efficiency.
Six hours after transfection, the transfection medium
Table 1 Clinical characteristics of patients with head and neck squamous cell carcinoma
Patients
(Tn)
Age/
gender
Tumor site Pathological
stage
Patients (Tm/
Lm)
Age/
gender
Tumor site Pathological
stage
No. No.
1 48/M Buccal mucosa T4N0M0 1 35/F Tongue T2N1M0
2 49/F Tongue T3N0M0 2 42/M Mandibular alveolar T2N1M0
3 60/F Buccal mucosa T2N0M0 3 59/M Buccal mucosa T4N2bM0
4 35/M Upper lip T1N0M0 4 62/F Mandibular gingival T4N2bM1
5 64/F Tongue T2N0M0 5 63/F Tongue T2N1M0
6 61/M Soft palate and buccal
mucosa
T1N0M0 6 53/M Buccal mucosa T2N2aM0
7 73/M Lower lip T1N0M0 7 72/F Tongue T1N2aM0
8 81/M Lower lip T1N0M0 8 65/F Tongue T2N2bM0
9 69/F Lower lip T2N0M0 9 50/M Tongue T2N1M0
10 55/M Tongue T1N0M0 10 72/M Mandibular gingival T4N1M0
11 76/M Buccal mucosa T2N0M0 11 41/M Tongue T2N1M0
12 56/F Mandibular gingiva T1N0M0 12 48/M Tongue and floor of
mouth
T3N2bM0
13 68/F Buccal mucosa T2N0M0 13 70/M Tongue T3N1MO
14 42/M Tongue T2N0M0 14 74/M Soft palate T4N1M0
15 73M Tongue T1N0M0 15 45/M Tongue T4N2bM0
16 42/F Tongue T2N0M0 16 62/M Tongue T2N1M0
17 52/F Tongue T2N0M0 17 56/M Floor of mouth T4N2cM0
18 50/M Tongue T1N0M0 18 55/M Tongue T4N2M0
19 51/F Mandibular gingival T3N0M0 19 51/M Buccal mucosa T3N2aM0
20 51/M Buccal mucosa T3N0M0 20 58/F Tongue T2N1M0
21 63/F Tongue T2N0M0 21 51/M Buccal mucosa T1N1M0
22 55/M Tongue T2N0M0 22 50/M Glottis T2N3M0
23 62/F Tongue T2N0M0 23 49/M Tongue T2N2M0
24 58/F Buccal mucosa T4N0M0 24 75/M Tongue T4N1M0
25 79/M Floor of mouth T4N0M0 25 42/F Tongue and floor of
mouth
T4N1M0
26 52/M Buccal mocosa T2N0M0 26 68/F Buccal mucosa T4N2aM0
27 78/F Mandibular alveolar T2N0M0 27 62/M Tongue T3N2bM0
28 30/M Tongue T3N0M0 28 62/F Mandibular gingival T2N2M0
29 42/F Mandibular gingival T1N0M0 29 36/M Tongue T4N2aM0
30 56/M Hard palate T1N0M0 30 50/M Tongue T4N1M0
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incubated at 37°C for an additional 48 hours. A second
group of cells was treated with TNFa (50 ng/ml) for 12
hours, and the luciferase activity was measured using
the Dual Luciferase System (Promega, USA).
Electromobility Shift Assay (EMSA)
DNA-binding assays were carried out using nuclear
extracts isolated from cells in the log phase of growth.
The nuclear extracts were isolated using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Pierce,
USA). Synthetic complementary oligonucleotides were
3′-biotinylated using a Biotin 3′-End DNA Labeling Kit
(Pierce) according to the manufacturer’si n s t r u c t i o n s
and annealed for two hours at room temperature. The
sequence of the oligonucleotides used is: 5′-AGTT-
GAGGGGACTTTCCCAGGC-3′ and 3′-TCAACTCCC
CTGAAAGGGTCCG-5′, which contains a putative
binding site for wild-type NF-B. Meanwhile, the other
sequence of the oligonucleotides used is: 5′-AGTT-
GAGGCGACCTTTAAAAGGC-3′ and 3′-TCAACTC
CCCTGAAAGGGTCCG-5′, which contains a mutant
NF-B binding site as the underline shown. The binding
reactions were carried out for 20 minutes at room tem-
perature in the presence of 50 ng/μL poly(dI-dC), 0.05%
Nonidet P-40, 5 mM MgCl2, 10 mM EDTA and 2.5%
glycerol in 1× binding buffer (LightShift Chemilumines-
cent EMSA Kit, Pierce) using 20 fmol of the biotin-
labeled target DNA and 5 μg of the nuclear extract. As
controls, lane 1 contained only the biotin-end-labeled
probe and lane 2 contained the labeled mutant probe
only. For the unlabeled and mutant probe competition,
extracts were pre-incubated with a 100-fold excess of
the unlabeled probe before the addition of the labeled
probe (lane 3 and lane 4). Both the biotin-end-labeled
probe and the nuclear extracts were added to lane 10 as
a positive control. Reactions were loaded into a native
4% polyacrylamide gel (pre-ran for 60 minutes) in 0.5 ×
Tris borate/EDTA, ran at 100 V and transferred onto a
positively charged nylon membrane (Hybond-N
+)i n0 . 5
× Tris borate/EDTA at 100 V for 30 minutes. The
transferred DNA was immediately cross-linked to the
membrane for 15 minutes on a UV transilluminator
equipped with 312 nm bulbs and detected using HRP-
conjugated streptavidin (LightShift Chemiluminescent
EMSA Kit) according to the manufacturer’s instructions.
Immunofluorescence
Cells were stimulated with either 50 ng/mL TNFa for
30 minutes, 100 μM pyrrolidine dithiocarbonate (PDTC)
or 10 μM BAY 11-7085 for 1 hour. Two additional
groups were treated with PDTC or BAY 11-7085 for 30
minutes and then TNFa was added for an additional 30
minutes. After incubation, the cells were fixed with 4%
formaldehyde and permeabilized with 0.1% Triton
X-100. After blocking in 3% BSA for 30 minutes, the
cells were incubated for one hour with an anti-human
p65 antibody (Santa Cruz, clone F-6, dilution 1:100),
then washed and incubated for 30 minutes with an
Alexa Fluor 488-conjugated anti-mouse IgG F(ab’)2 frag-
ment (Invitrogen Molecular Probe, dilution 1:200) at
room temperature in the dark. The cells were washed
three times with PBS containing 0.02% Tween 20 and
mounted in aqueous mounting medium containing 0.5
mg/ml 40-6-diamidino-2-phenylindole to stain the
nuclei. Three random visual fields at a 200 × magnifica-
tion were observed using a Leica TCS SP2 confocal
spectral microscope.
Cell migration assays
The effect of NF-B activation on cell migration was
examined using Matrigel Invasion Chambers, as sug-
gested by the manufacturer (BD Bioscience). The upper
surface of the chamber contained the transwell filter (8
μmp o r e s )c o a t e dw i t hM a t r i g e l, fibronectin and vitro-
nectin. Cells (1×10
5) were collected and placed in the
upper chamber with 50 ng/ml TNFa,1 0 0μM PDTC or
10 μM BAY 11-7085. Treated cells with the vehicles of
above reagents were used as a control. The cells were
incubated for 24 hours in a humidified tissue culture
i n c u b a t o ra t3 7 ° Ca n d5 %C O 2. The next day, a cotton-
tipped swab was used to remove the non-invading cells
Table 2 Clinical correlation
Characteristics Tn Tm/Lm df c
2 P-value
Age(year)* 0.5776
Mean 57.7 55.9
Std Dev 13.1 11.3
Sex 1 1.763 0.184
Male 16 21
Female 14 9
Smoking habit 1 2.052 0.152
Yes 6 11
No 24 19
Alcohol use 1 0.287 0.592
Yes 10 12
No 20 18
Tumor site 2 2.400 0.121
Tongue 12 18
Other sites 18 12
Differentiation 1 17.778 0.001
WD 20 4
MOD/PD 10 26
Abbreviations: PD, poor differentiated; WD, well differentiated; MOD,
moderate differentiated.
*P value was obtained using grouped t test, others were obtained using c
2 or
Wilcoxon Rank-sum Test for comparison between two groups or more than
two groups, respectively.
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Page 4 of 13by applying gentle but firm pressure while moving the
tip around the membrane surface. The cells on the
lower surface of the insert were stained with hematoxy-
lin for 10 minutes. The number of invading cells was
counted using a microscope at a 400× magnification,
and the mean number of cells per field in five random
fields was recorded. The extent of cell invasion is
expressed as the fold increase in the total number of
cells on the lower surface of the chamber in the treated
samples compared to the total number of invading cells
in the untreated samples.
Mice Injected with Tb Cells and PDTC Treatment
Female 4- to 5-week-old nu/nu Balb/C mice (18-20 g)
were maintained in a specific pathogen-free animal facil-
ity of the Laboratory of Animal Experiment Affilited to
Ninth People’s Hospital, Shanghai Jiao Tong University
School of Medicine. There were 10 mice in each group.
Logarithmically growing Tb cells were harvested and
injected into the tail vein of the mice at a dose of 2×10
6
cells per mouse. The mice were injected intraperitone-
ally (i.p) with PDTC (Sigma-Aldrich) at a concentration
of 1 mM/kg/day in 100 μl of PBS for 14 days beginning
on the day of the injection of the Tb cells. Control ani-
mals received 100 μl of PBS alone. The mice were
checked daily for weight loss and trouble breathing as a
sign of massive lung metastases. All the mice were
euthanized when the control mice lost 30% of their
body weight due to lung metastasis (an average of six
weeks after the tail vein injection). The lungs were
excised and collected in PBS, and the lung weight was
determined for each individual animal. For histological
analysis of metastasis, the lungs were immersed in 10%
neutral buffered formalin before paraffin embedding and
sectioning. Sections (5 μm thick) were stained using
hematoxylin and eosin (H&E) and evaluated. The total
number of metastases per lung was determined by col-
lection of serial lung sections, selection of sections
approximately 0.3 mm apart and counting the number
of metastatic lesions. Large metastatic lesions that
appeared in more than one section were only counted
once.
Mice Injected with TL Cells and PDTC or BAY 11-7085
Treatment
Female 4- to 5-week-old Balb/C
nu/nu mice were main-
tained as described above. The mice were divided into
three groups: a control group, a PDTC group and a
BAY 11-7085 group, with five mice in each group. Loga-
rithmically growing TL cells were harvested and injected
into the foot pads of the mouse at a dose of 2×10
6 cells
for each foot pad. Three weeks after injection, the mice
were injected intraperitoneally (i.p) with either 50 mM/
kg/day of PDTC (Sigma-Aldrich) or 5 mM/kg/day of
BAY 11-7085 (Calbiocham) in 100 μlP B Sf o r1 4d a y s .
Control animals received 100 μlP B Sa l o n e .T h em i c e
were checked daily for weight loss and popliteal fossa
lymph node metastasis. All the mice were euthanized an
average of nine weeks after injection. For histological
analysis of metastasis, the popliteal fossa lymph nodes
were excised and immersed in 10% neutral-buffered for-
malin before paraffin embedding and sectioning. Sec-
tions (5 μm thick) were processed for H&E staining and
histological evaluation. The number of lymph nodes
with metastases was determined by three pathologists.
Annexin V/PI staining
Tca8113 and TL cells (1×10
6) treated with TNFa
(50 ng/ml), PDTC 100 μM and BAY 11-7085(10 μM)
alone or with TNFa plus PDTC or plus BAY 11-7085
for 24 hours were labeled with FITC-conjugated
Annexin V and propidium iodide (PI) using the Annexin
V-FITC/PI Apoptosis Detection Kit (BD Pharmingen)
according to the manufacturer’sp r o t o c o l .T h es t a i n e d
cells were analyzed using flow cytometry (FACScalibur,
Becton Dickinson, Rutherford, NJ) to distinguish
between viable (Annexin V-/PI-), early apoptotic
(Annexin V+/PI-), late apoptotic (Annexin V+/PI+) or
dead (Annexin V-/PI+) cells. The apoptotic rate was cal-
culated as the percentage of early apoptotic cells plus
the percentage of late apoptotic cells.
Results
Expression of NF-B p65 in Primary SCCHN Tumors and
Lymph Node Metastases
The expression of NF-B p65 in primary SCCHN
tumors and lymph node metastases was examined using
immunohistochemistry. The clinical parameters of the
patients are shown in Table 1. The tissue samples
included 30 primary tumors with lymph node involve-
ment (Tm), along with their lymph node contain metas-
tases (Lm), and 30 primary tumors without lymph node
involvement (Tn) specimens. No significant differences
were found in age (t = 0.5600, p = 0.5776), gender (c
2 =
1.763, p = 0.184), alcohol use (c
2 = 0.287, p =0 . 5 9 2 ) ,
smoking habit (c
2 =2 . 0 5 2 ,p =0 . 1 5 2 )o rt u m o rs i t e
(c
2 = 2.400, p = 0.121) between the patients in the Tn
group or the Tm/Lm groups (Table 2). As the transloca-
tion of p65 from the cytoplasm to the nucleus is
required for NF-B/relA signaling, the specimens were
evaluated for nuclear p65 expression. As shown in Fig.
1a, p65 was markedly expressed in almost all of the
SCCHN specimens. Positive nuclear staining was
observed in 23% and 52% of primary tumors without
lymph node involvement and primary tumors with
lymph node involvement, respectively. Of the three
groups, nuclear staining for p65 was most prevalent in
lymph node contain metastases (61%) (Fig. 1b). The
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ent between the Tn, Tm and Lm groups (Wilcoxon rank-
sum test; c
2 = 37.489, df =2 ,p = 0.001) (Fig. 1b). As half
of the SCCHN samples were tongue squamous cell carci-
noma, the statistic analysis was taken for squamous cell
carcinoma in tongue and in other sites of head and neck
individually. The similar results showed that the nuclear
positive rates of NF-Bp 6 5i nL ma n dT mg r o u p sw e r e
higher than Tn group (Wilcoxon rank-sum test; c
2 =
14.573, df =2 ,p = 0.001 in tongue group and c
2 = 22.425,
df =2 ,p = 0.0001 in other site of head and neck group,
respectively). These data demonstrate that NF-B/relA
activity can be correlated with SCCHN metastasis.
Increased Constitutive NF-B/relA Activity in Metastatic
Human SCCHN Cell Lines and Increased Sensitivity
to TNFa
To determine whether constitutive NF-B/relA activity
was present in SCCHN cells, we used a western blot to
determine the level of phospho-IBa in a number of
SCCHN cells lines. The level of phospho-IBa was high
in the highly metastatic cell lines (Tb, TL and OSC-4),
and phospho-p65 was highly expressed in the Tb and
TL cell lines (Fig. 2a). Next, we co-transfected a 2 ×
NF-B-Luc reporter and a pPenilla Renilla reporter into
these five SCCHN cell lines and assayed luciferase activ-
i t y .A ss h o w ni nF i g .2 b ,t h eb a s a lN F - Bp r o m o t e r
activity was significantly higher in the metastatic cell
lines (Tb, TL, and OSC-4). When the cells were treated
with TNFa,N F - B promoter activity was further
increased in the highly metastatic cell lines. Moreover,
as detected using a western blot, IBa was degraded
more quickly in the Tb and TL cell lines. The constitu-
tive NF-B activities were significantly increased by the
stimulation of TNFa in the Tb and TL cell lines (Fig.
2c). To confirm the high constitutive NF-B activity in
the highly metastatic cell lines, an EMSA was performed
using nuclear extracts. While all of the five SCCHN cell
lines showed NF-B DNA-binding activity (Fig. 2d), the
DNA binding was significantly higher in the highly
metastatic cells lines (Tb, TL and OSC-4) compared to
the cells with lower metastatic potential (TSCC and
Tca8113).
Down-regulation of Constitutive NF-B/relA Activity
stimulated by TNFa in Metastatic Human SCCHN Cells
Treated with PDTC or BAY 11-7085
In order to use nuclear localization of p65 as a surrogate
for NF-KB activity, the subcellular localization of NF-B
p65 was evaluated using immunofluorescence and con-
focal microscope. As shown in Fig. 3, the NF-B activity
was significantly higher in TL cells when treated with
TNFa. TNFa promoted the rapid nuclear localization of
p65. Whereas in PDTC- or BAY 11-7085-treated cells,
TNFa stimulation could not promote the translocation
of p65 from the cytoplasm to the nucleus.
Suppression of Cell Migration in SCCHN Cells Treated
with PDTC or BAY 11-7085
The effect of NF-B activity on the migration of the
highly metastatic SCCHN cell lines was evaluated using
established an in vitro assay system. Tb and TL cell
migration was inhibited 26.2% and 31.4%, respectively,
when treated with PDTC and was inhibited 24.8% and
Figure 1 Immunologic detection of NF-B p65 in SCCHN tissues. (a) Representative images of p65 immunostaining of a primary tumor with
lymph node involvement (N+) (Tm), the corresponding lymph node contain metastases (Ln) from the same patient and a primary tumor
without lymph node involvement (N-) (Tn). (b) Graphical representation of the percentage of p65-positive nuclei in the SCCHN tissue. The
asterisk (*) denotes p < 0.01.
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(Fig. 4a). Moreover, the migration of Tb cells was inhib-
ited 36.2% and 41.6% when the cells were treated with
either PDTC and TNFa or BAY 11-7085 and TNFa,
respectively. TL cell migration was inhibited 52.0% and
58.0% following treatment with PDTC and TNFa or
BAY 11-7085 and TNFa, respectively. Both PDTC and
BAY 11-7085 produced a significant decrease in tumor
cell migration (p = 0.001), and TNFa stimulation further
decreased cell migration when the NF-Bp a t h w a yw a s
inhibited (p < 0.05).
Decreased Hematologic and lymphatic Metastasis of
SCCHN Cell Lines Following Inhibition of NF-B
To determine the effect of the NF-Bp a t h w a yo n
metastasis, Tb cells were injected into the lateral tail
vein of mice, and these mice were treated with PDTC
or with PBS (control) for two weeks. Six weeks after
injection, both the PDTC-treated group and the control
group developed metastases (Fig. 4b). Additionally, the
Tb-PDTC group had significantly fewer (p = 0.0002)
metastases (average number of 11.8 metastases per lung)
than the control group (average number of 72.2 metas-
tases per lung; Fig. 4b, left and middle panels). Addi-
tionally, the mice injected with Tb cells and treated with
PDTC to block NF-B activity showed a two-fold
decrease in lung weight (Fig. 4b, right panel; p =
0.0002).
To further characterize the effect of NF-B activity of
metastasis, TL cells were injected into the hibateral foot
pads of mice. The mice were either treated with PBS
(control) or treated with PDTC or BAY 11-7085 for two
Figure 2 Constitutive NF-B activity in SCCHN cell lines. (a) Western blot analysis of phosphorylated IBa (serine 32) and phosphorylated
NF-B p65 (serine 536). (b) Constitutive NF-B promoter activity. The asterisk (*) denotes p < 0.01 compared to untreated cells. The data shown
are from one representative experiment out of three independent experiments. The bars indicate the standard deviation. (c) Western blot
analysis of IBa degradation and phosphorylated NF-B p65 (serine 536) expression following treatment with TNFa for the indicated time. (d)
NF-B binding activity. Nuclear protein was extracted from HNSCC cells, and an EMSA was performed as described previously. The image is
representative of three independent experiments.
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nodes containing metastases was counted by three
pathologists (Fig. 4c). In the control group, eight lymph
nodes were positive for lymph node metastases, whereas
two of the lymph nodes in the PDTC group had metas-
tases, and one lymph node in the BAY 11-7085 group
contained a metastasis (Fig. 4c2). These results demon-
strate that decreased NF-B activity leads to suppression
of tumor metastasis.
Cell Apoptosis Induced by PDTC or BAY 11-7085 and
Sensitivity to TNFa
To determine whether inhibition of NF-Bb yP D T Co r
BAY 11-7085 increases the percentage of apoptotic cells
and renders metastatic cancer cells sensitive to TNFa-
mediated killing, apoptosis was measured using Annexin
V staining following treatment with PDTC, BAY 11-
7085 and/or TNFa (Fig. 5a). The rate of apoptosis in
Tca8113 cells treated with PDTC or BAY 11-7085
reached to 6.59% and 7.18% from 2.62%, respectively,
and the rate reached to 6.90% and 8.53% from 5.83% in
TL cells treated with PDTC or BAY 11-7085, respec-
tively (Fig. 5b). The percentage of apoptotic TL cells fol-
lowing treatment with PDTC or BAY 11-7085 was not
significantly greater than either the control group or the
TNFa treated group (p >0 . 0 5 ) .H o w e v e r ,T c a 8 1 1 3a n d
TL cells treated with PDTC or BAY 11-7085 were more
sensitive to TNFa-mediated killing (p = 0.0003)
compared to the cells treated with TNFa alone. Signifi-
cant differences in the apoptotic rate were found
between the cells with lower metastatic potential
(Tca8113) and the cells with higher metastatic potential
(TL) after treatment with PDTC or BAY 11-7085
(p = 0.0120).
Down-regulation of Metastasis-Associated Gene
Expression in PDTC-treated Metastatic SCCHN Cells
Genes, such as vascular endothelial growth factor
(VEGF) and matrix metalloproteinase-9 (MMP9), have
been reported to be linked to tumor metastasis, and
NF-B binding sites have been identified in their pro-
moters. Therefore, we examined whether PDTC treat-
ment down-regulated VEGF and MMP9 expression in
metastatic SCCHN cells. Tb cells were treated with
PDTC for the indicated times and whole-cell extracts
were prepared and analyzed using a western blot. PDTC
treatment inhibited VEGF and MMP9 expression in a
time-dependent manner (Fig. 5c). Similar results were
found in TL cells treated with PDTC or BAY 11-7085
(data not shown).
Discussion
The expression of p65 and IB proteins in SCCHN spe-
cimens, normal mucosa and epithelial dysplasia speci-
mens has been examined by immunohistochemistry.
Several studies have suggested that the biological
Figure 3 Inhibition of NF-B p65 nuclear localization by PDTC and BAY 11-7085. The p65 expression in cells were observed using a Leica
TCS SP2 confocal microscope. TNFa could promote the rapid nuclear localization of p65. Whereas, TNFa stimulation could not promote the
translocation of p65 from the cytoplasm to the nucleus in PDTC- or BAY 11-7085-treated cells.
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Page 8 of 13Figure 4 Suppression of cell migration and metastasis in SCCHN cells following inhibition of the NF-B signaling pathway.
(a) Treatment with either PDTC or BAY 11-7085 significantly decreased tumor cell invasion. TNFa stimulation further down-regulated cell
invasion. (b) Decreased lung metastasis of Tb cells in nude mice. The weight of the lung was measured. The asterisk (*) indicates p < 0.01. (c)
Decreased lymph node metastasis of TL cells in nude mice. The popliteal fossa lymph nodes were excised. (c1)Of 10 mice in each group,
metastases were detected in eight lymph nodes in the control group, two in the PDTC group and one in the BAY 11-7085 group (c2). The
popliteal fossa lymph nodes sections were observed using microscopy at 5× magnification (c3).
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Page 9 of 13characters of SCCHN are correlated with the activity of
NF-B pathway [14,15]. Based on those findings, altera-
tions in NF-B activity may contribute to tumor inva-
sion and metastasis in vivo. To confirm this possibility,
we first assessed the activity of NF-B pathway by
observation of p65 nuclear localization in specimens
from the patients with SCCHN. Our results show that
the level of NF-B activity differs significantly between
primary tumors without lymph node involvement and
primary tumors with lymph node involvement, as well
as the metastatic lymph node. Furthermore, we have
confirmed these clinical results through in vitro and in
vivo experiments, suggesting that NF-B activity contri-
butes to SCCHN hematologic and lymphatic metastasis.
To study NF-B activation and its role in SCCHN
invasion and metastasis, we established the Tca8113
SCCHN cell line and generated the highly metastatic
subclones, Tb and TL, through a combination of in vivo
selection and in vitro cloning. Since the Tca8113, Tb
and TL cell lines share an identical genetic background,
we presumed that differentially expressed proteins and
that different levels of signaling pathway activity play
direct or indirect roles in invasion and metastasis. To
solidify the data presented here, two additional SCCHN
cell lines were added to the study, the poorly metastatic
TSCC cell line and the strongly metastatic OSC-4 cell
line. Using these five cell lines, we investigated the rela-
tionship between the level of NF-B activity and
SCCHN metastatic behaviour to explore the mechanism
underlying SCCHN metastasis.
Our results show that the treatment of highly meta-
static SCCHN cells with NF-B inhibitors significantly
reduced cell invasion in vitro, while the apoptotic rates
in highly metastatic cells have not been significantly
increased compared with the lower metastatic Tca8113
cells. Furthermore, NF-B inhibitors significantly
Figure 5 Cell Apoptosis Induced by PDTC or BAY 11-7085 and Sensitivity to TNFa. (a) Apoptosis induced by PDTC or BAY 11-7085 and
sensitivity to TNFa. The data are from one representative experiment out of three independent experiments. (b) Cells treated with PDTC or BAY
11-7085 were more sensitive to TNFa-mediated killing; the asterisk (*) denotes p < 0.01. (c) Down-regulation of VEGF and MMP9 expression in
PDTC-treated Tb cells.
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metastasis of TL cells to the lymph node in vivo.T h e s e
results demonstrate that inhibition of NF-B/relA activ-
ity through suppression of IBa phosphorylation and a
r e d u c t i o ni nt h ef o r m a t i o no fa c t i v eN F - Bi sa b l et o
reduce tumor invasion and metastasis.
In our study, using both human cancer specimens and
cell lines, clearly shows that NF-B/relA activity signifi-
cantly contributes to the metastasis of SCCHN.
Although constitutive activation of NF-B/Rel family
members has been reported in several cancers [14-17],
o u rd a t ai st h ef i r s tt i m et od e m o n s t r a t et h a tN F - B
activity contributes to hematologic and lymphatic
metastasis of SCCHN.
The mechanisms underlying high NF-B/relA activity
in SCCHN and other human cancer cell types are not
clear. NF-B has been reported to strongly regulate cell
apoptosis in many tumor cells [18], which may be one
of the possible mechanisms by which NF-B inhibits
cell invasion and metastasis. Our results show that NF-
B inhibitors could induce cell apoptosis. However, no
significant difference in the apoptotic rate of cell lines
with different metastatic potential was seen compared to
the control groups. Therefore, there may be other
mechanism contributing to NF-B activity in SCCHN
metastasis. Some studies have reported that the treat-
ment of cancer cells with antisense RNA targeting p65
inhibited tumor cell adhesion and growth both in vitro
and in vivo [19]. Studies have also demonstrated that
NF-B could regulate several proteins that promote
tumor growth, invasion and metastasis, such as uroki-
nase-type plasminogen activator and MMP9 [20,21]. In
the present study, we found that proteins related to cell
metastasis, including VEGF and MMP9, were down-
regulated following inhibition of NF-B, suggesting that
these proteins may contribute to SCCHN metastasis.
These data are consistent with previous studies examin-
ing other cancer cell lines.
Additionally, our results show that TNFa significantly
induced the apoptosis of SCCHN cells treated with an
NF-B inhibitor. Recently, several studies have found
that NF-B functions as a tumor promoter in inflamma-
tion-associated cancer [6,22-24]. This finding may be
the missing link between inflammation and cancer. As a
result of this observation, many researchers have begun
to focus on the interaction between the host environ-
ment and tumor cells. This tumor-host interaction
could play a role in high level of NF-B/RelA activity
observed in malignant cells because the development of
cancer metastases is determined by the interaction of
tumor cells with their immediate environment, including
tissue- or organ-specific cytokines [25]. A number of
different stimuli can activate NF-B. For example,
inflammatory signals, hypoxia [26,27] and oncogenic
proteins, such as mutated Ras [28], have been shown to
regulate NF-B activity. We observed that highly meta-
static SCCHN cell lines constitutively produce proin-
flammatory cytokines, including TNFa, interleukin 1 a
(IL-1a), IL-6, IL-8 and granulocyte macrophage-colony
stimulating factor. Furthermore, the treatment of Tb or
TL cells with PDTC or BAY 11-7085 inhibits the
expression of these inflammatory cytokines (data not
shown), which are known to activate the NF-Bp a t h -
way and to be induced in response to the activation of
NF-B/RelA-mediated transcription. Therefore, NF-B
activation, and a positive feedback loop, seems to play
an important role in tumor metastasis. Additionally, NF-
B activation and interactions with the microenviron-
ment most likely plays an important role not only in
carcinogenesis, especially inflammation-associated can-
cers, but also in tumor invasion and metastasis.
Preliminary results have suggested that highly meta-
static SCCHN cells are more sensitive to TNFa.S i m i -
larly, we found that the phosphorylation of p65 on
serine 536 is increased in metastatic SCCHN cells. A
number of recent studies have suggested that p65 phos-
phorylation may be necessary for transcriptionally com-
petent nuclear NF-B [29-32]. The lack of either of the
kinases involved in NF-B activation resulted in the
normal activation of NF-B in response to a wide vari-
ety of inducers, as measured by IBa degradation, NF-
B nuclear translocation or binding to DNA; however,
nuclear NF-B was unable to drive transcription [33,34].
We hypothesize that the basal phosphorylation of p65
on serine 536 increased p65 transcription, thereby
improving sensitivity to TNFa. Although Wang et al.
reported that stimulation of cells with TNFa resulted in
inducible p65 phosphorylation at position 529 [35], we
detected increased phosphorylation of p65 on serine 536
when the cells were treated with TNFa.T h i sr e s u l ti s
consistent with a recent study that has suggested that
TNFa can induce the phosphorylation of p65 on serine
536 [36]. In addition, several studies have shown that
IL-1, lipopolysaccharide and phosphoinositide 3-kinase/
Akt induced p65 phosphorylation on serine 536
[29,37-40], and overexpression of phosphorylated NF-B
were significant predictors of poor survival of tumor
patients [41]. Therefore, we hypothesize that p65 phos-
phorylated on serine 536 may interact with additional
signaling pathways that play an important role in
SCCHN metastasis. Experiments testing this hypothesis
are currently under investigation.
Conclusions
Taking together, our previous and present studies
demonstrate that NF-B activity can be significantly
correlated with SCCHN metastasis. The inhibition of
the constitutive activity of the NF-B signaling pathway
Yan et al. BMC Cancer 2010, 10:437
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Page 11 of 13reduces tumor hematologic and lymphatic metastasis
through decreased expression of several proteins and
cytokines related to metastasis. Therefore, the NF-B
pathway and its signaling effectors may be promising
biomarkers to detect and treat SCCHN metastasis.
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